{rfName}
Ga

Indexed in

License and use

Citations

14

Altmetrics

Grant support

The authors are sincerely grateful to START San Antonio and START Madrid-FJD for providing the SCLC-PDX sample. The authors also thank the Animal Model Core Facility of IIS-Fundacion Jimenez Diaz (ES28079000089).

Analysis of institutional authors

Garcia-Foncillas JAuthorDomine MCorresponding Author

Share

November 28, 2022
Publications
>
Article
No

Galectin-1, a novel promising target for outcome prediction and treatment in SCLC

Publicated to:BIOMEDICINE & PHARMACOTHERAPY. 156 113987-113987 - 2022-12-01 156(), DOI: 10.1016/j.biopha.2022.113987

Authors: Corral JM, Puerto-Nevado LD, Cedeño M, Río-Vilariño A, Mahillo-Fernández I, Galeano C, Baños N, García-Foncillas J, Dómine M, Cebrián A

Affiliations

Biostatistics Unit, IIS-Fundación Jiménez Díaz University Hospital-UAM, Madrid, Spain. - Author
Medical Oncology Department, Hospital Fundación Jiménez Díaz-UAM, Madrid, Spain. Electronic address: MDomine@fjd.es. - Author
Pathology Department, IIS-Fundacion Jimenez Diaz-UAM, Madrid, Spain. - Author
Preclinical program START Madrid-FJD, Hospital Fundación Jiménez Díaz-UAM, Madrid, Spain. - Author
Thoracic Surgery Department, Hospital Fundación Jiménez Díaz-UAM, Madrid, Spain. - Author
Translational Oncology Division, IIS-Fundación Jiménez Díaz-UAM, Madrid, Spain. - Author
Translational Oncology Division, IIS-Fundación Jiménez Díaz-UAM, Madrid, Spain. Electronic address: arancha.cebrian@quironsalud.es. - Author
Translational Oncology Division, IIS-Fundación Jiménez Díaz-UAM, Madrid, Spain. Electronic address: lpuerto@quironsalud.es. - Author
UAM, Hosp Fdn Jimenez Diaz, Med Oncol Dept, Ave Reyes Catolicos 2, Madrid 28040, Spain - Author
UAM, Hosp Fdn Jimenez Diaz, Preclin Program START Madrid, FJD, Madrid, Spain - Author
UAM, Hosp Fdn Jimenez Diaz, Thorac Surg Dept, Madrid, Spain - Author
UAM, Pathol Dept, Fdn Jimenez Diaz, IIS, Madrid, Spain - Author
UAM, Translat Oncol Div, Fdn Jimenez Diaz, IIS, Ave Reyes Catolicos 2, Madrid 28040, Spain - Author
UAM, Univ Hosp, Biostat Unit, IIS,Fdn Jimenez Diaz, Madrid, Spain - Author
See more

Abstract

small-cell lung cancer (SCLC) is one of the most lethal malignancies. Its management is complex due to the lack of biomarkers and limited therapies. Galectin-1 (Gal-1) plays a major role in cancer development and progression. The aim of this study is to assess whether Gal-1 has a predictive role in the disease evolution and its therapeutic potential.The expression level of Gal-1 was examined by using a public RNA-sequencing (77 SCLC patients) and in-house immunohistochemistry (IHC) performed on biopsies from 81 patients. Survival curves and Cox regression analysis were used to assess the prognostic potential of Gal-1. In addition, a SCLC-PDX model was carried out and treated with either OTX008, an inhibitor of Gal-1, or vehicle to assess the effects of Gal-1 inhibition on this disease in vivo.Galectin-1 gene (LGALS1) expression showed a strong negative correlation with outcome in SCLC patients with advanced disease (p = 0.007). IHC unveiled that overall survival (OS) was significantly lower among extensive-stage SCLC (ES-SCLC) patient group with increased level of Gal-1 and platelet-to-lymphocyte ratio (PLR) (HR=3.07, 95% CI: 1.62, 5.79, p < 0.001). The SCLC-PDX model showed a significant reduction in tumor size (tumor growth inhibition [TGI] index 73%) without side effects.in this study, high levels of Gal-1 and PLR were associated with poorer OS in SCLC patients, supporting their utility as clinical prognostic biomarkers. Moreover, the in vivo model suggests the inhibition of Gal-1 as a novel potential therapy for this disease with very poor prognosis.Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Keywords

cancer progressiongal-1 inhibitorgalectin-1hepatocellular-carcinomainhibitormetastasisotx008plateletplatelet -to -lymphocyte ratioprognosisprognostic-significanceproteinstrategyGal-1 inhibitorGalectin-1Platelet-to-lymphocyte ratioPrognosisSmall cell lung cancerTo-lymphocyte ratio

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal BIOMEDICINE & PHARMACOTHERAPY due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position 22/278, thus managing to position itself as a Q1 (Primer Cuartil), in the category Pharmacology & Pharmacy. Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 3.63, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-16, the following number of citations:

  • WoS: 3
  • Europe PMC: 3

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-16:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 10.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 11 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 2.6.
  • The number of mentions on the social network X (formerly Twitter): 4 (Altmetric).

Leadership analysis of institutional authors

the author responsible for correspondence tasks has been DOMINE GOMEZ, MANUEL.